Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease

Restorative Neurology and Neuroscience

Volumn 21, Issue 3-4, 2003, Pages 191-209

  Otto, Markus ^a   Wiltfang, Jens ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN 14 3 3; PROTEIN S100B; TAU PROTEIN;

ALZHEIMER DISEASE; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; LABORATORY DIAGNOSIS; PRION DISEASE; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 0142164877     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (215)

1. A. Alperovitch, P. Brown, T. Weber and M. Pocchiari et al., The incidence of Creutzfeldt-Jakob disease in Europe in 1993, Lancet 334(8902) (1994), 918.
2. S. Poser, T. Weber, I. Zerr and A. Giese et al., Keine Häufung der Creutzfeldt-Jakob-Krankheit in der Bundesrepublik Deutschland, Deutsches Ärzteblatt 93(34-35) (1996), A-2149-2150.
3. P. Brown, C.J.J. Gibbs, P. Rodgers-Johnson and D.M. Asher et al., Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease, Ann Neurol 35(5) (1994), 513-529.
4. S. Poser, I. Zerr, W.J. Schulz-Schaeffer, H.A. Kretzschmar and K. Felgenhauer, Die Creutzfeldt-Jakob-Krankheit. Eine Sphinx der heutigen Neurobiologie [The Creutzfeldt-Jakob disease. A sphinx of current neurobiology], Dtsch Med Wochenschr 122(37) (1997), 1099-1105.
5. R.G. Will, J.W. Ironside, M. Zeidler and S.N. Cousens et al., A new variant of Creutzfeldt-Jakob disease in the UK [see comments], Lancet 347(9006) (1996), 921-925.
6. H.G. Creutzfeldt, Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems (vorläufige Mitteilung), Z ges Neurol Psychiat 57 (1920), 1-18.
7. A. Jakob, Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde (spastische Pseudosklerose- Encephalomyelopathie mit disseminierten Degenerationsherden), Dtsch Z Nervenheilk 70 (1921), 132-146.
8. T. Weber, I. Zerr, M. Bodemer and S. Poser, Erweitertes Krankheitsspektrum humaner spongiformer Enzephalopathien oder Prionkrankheiten, Nervenarzt 68(4) (1997), 309-323.
9. F. Katscher, It's Jakob's disease, not Creutzfeldt's, Nature 393(3380) (1998), 11.
10. H.A. Kretzschmar, M. Neumann and D. Stavrou, Codon 178 mutation of the human prion protein gene in a German family (Backer family): sequencing data from 72-year-old celloidin-embedded brain tissue, Acta Neuropathol 89 (1995), 96-98.
11. J.G. Collee and R. Bradley, BSE: a decade on - Part I, Lancet 349(9052) (1997), 636-641.
12. M.E. Bruce, R.G. Will, J.W. Ironside and I. McConnell et al., Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent, Nature 389(6650) (1997), 498-501.
13. A.F. Hill, M. Desbruslais, S. Joiner and K.C. Sidle et al., The same prion strain causes vCJD and BSE, Nature 389(6650) (1997), 448-450.
14. M.R. Scott, R. Will, J. Ironside and H.O. Nguyen et al., Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans, Proc Natl Acad Sci USA 96(26) (1999), 15137-15142.
15. G.A. Venters, New variant Creutzfeldt-Jakob disease: the epidemic that never was, Bmj 323(7317) (2001), 858-861.
16. C.M. van Duijn, N. Delasnerie-Laupretre, C. Masullo and I. Zerr et al., Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-1995. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD), Lancet 351(9109) (1998), 1081-1085.
17. S. Collins, M.G. Law, A. Fletcher and A. Boyd et al., Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study, Lancet 353 (1999), 693-697.
18. B. Chesebro, BSE and prions: uncertainties about the agent, Science 279(5347) (1998), 42-43.
19. H. Diringer, Proposed link between transmissible spongiform encephalopathies of man and animals, Lancet 346(8984) (1995), 1208-1210, Issn: 0140-6736.
20. H. Diringer, Creutzfeldt-Jakob disease, Lancet 347(9011) (1996), 1332-1333.
21. H. Diringer, M. Beekes, M. Ozel and D. Simon et al., Highly infectious purified preparations of disease-specific amyloid of transmissible spongiform encephalopathies are not devoid of nucleic acids of viral size, Intervirology 40(4) (1997), 238-246.
22. J.S. Griffith, Self-replication and scrapie, Nature 215(105) (1967), 1043-1044.
23. S.B. Prusiner, Novel proteinaceous infectious particles cause scrapie, Science 216 (1982), 136-144.
24. H.A. Kretzschmar, L.E. Stowring, D. Westaway and W.H. Stubblebine et al., Molecular cloning of a human prion protein cDNA, Dna 5(4) (1986), 315-324.
25. A. Sailer, H. Bueler, M. Fischer, A. Aguzzi and C. Weissmann, No propagation of prions in mice devoid of PrP, Cell 77(7) (1994), 967-968.
26. P. Parchi, R. Castellani, S. Capellari and B. Ghetti et al., Molecular Basis of Phenotypic Variability in Sporadic Creutzfeldt-Jakob Disease, Annals of Neurology 39(6) (1996), 767-778.
27. J. Safar, H. Wille, V. Itri and D. Groth et al., Eight prion strains have PrP(Sc) molecules with different conformations, Nat Med 4(10) (1998), 1157-1165.
28. A.F. Hill, M. Antoniou and J. Collinge, Protease-resistant prion protein produced in vitro lacks detectable infectivity, J Gen Virol 80(Pt 1) (1999), 11-14.
29. C.I. Lasmezas, J.P. Deslys, O. Robain and A. Jaegly et al., Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein, Science 275(5298) (1997), 402-405.
30. R.S. Hegde, J.A. Mastrianni, M.R. Scott and K.A. DeFea et al., A transmembrane form of the prion protein in neurodegenerative disease, Science 279(5352) (1998), 827-834.
31. R.S. Hegde, P. Tremblay, D. Groth and S.J. DeArmond et al., Transmissible and genetic prion diseases share a common pathway of neurodegeneration, Nature 402(6763) (1999), 822-826.
32. R. Chiesa and D.A. Harris, Prion diseases: what is the neurotoxic molecule? Neurobiol Dis 8(5) (2001), 743-763.
33. J. Hope, Spongiform encephalopathies. Breech-birth prions, Nature 402(6763) (1999), 737, 739.
34. J. Ma and S. Lindquist, Conversion of PrP to a Self-Perpetuating PrPSc-like Conformation in the Cytosol, Science 298(5599) (2002), 1785-1788.
35. J. Ma, R. Wollmann and S. Lindquist, Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol, Science 298(5599) (2002), 1781-1785.
36. S.B. Prusiner, M. Scott, D. Foster and K.M. Pan et al., Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication, Cell 63(4) (1990), 673-686.
37. J.T. Jarrett and P.T. Lansbury, Jr., Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73(6) (1993), 1055-1058.
38. M. Eigen, Prionics or the kinetic basis of prion diseases, Biophys Chem 63(1) (1996), A1-18.
39. H. Kretzschmar, [Transmissible spongiform encephalopathies (prion diseases) - molecular principles and in vitro models], Wien Med Wochenschr 148(4) (1998), 67-73.
40. D.R. Brown, K. Qin, J.W. Herms and A. Madlung et al., The cellular prion protein binds copper in vivo, Nature 390(6661) (1997), 684-687.
41. C Directly Interacts with Proteins Involved in Signaling Pathways, J Biol Chem 276(48) (2001), 44604-44612.
42. J. Herms, T. Tings, S. Gall and A. Madlung et al., Evidence of presynaptic location and function of the prion protein, J Neurosci 19(20) (1999), 8866-8875.
43. I. MacGregor, J. Hope, G. Barnard and L. Kirby et al., Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components, Vox Sang 77(2) (1999), 88-96.
44. K. Holada and J.G. Vostal, Different levels of prion protein (PrPc) expression on hamster, mouse and human blood cells, Br J Haematol 110(2) (2000), 472-480.
45. O. Windl, M. Dempster, J.P. Estibeiro and R. Lathe et al., Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene, Hum Genet 98(3) (1996), 259-264.
46. M.S. Palmer and J. Collinge, Mutations and polymorphisms in the prion protein gene, Hum Mutat 2(3) (1993), 168-173.
47. J.L. Laplanche, N. Delasnerie Laupretre, J.P. Brandel and J. Chatelain et al., Molecular genetics of prion diseases in France, Neurology 44(12) (1994), 2347-2351.
48. J. Collinge, M.S. Palmer and A.J. Dryden, Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease, Lancet 337(8755) (1991), 1441-1442.
49. P. Brown, M. Preece, J.P. Brandel and T. Sato et al., Iatrogenic Creutzfeldt-Jakob disease at the millennium, Neurology 55(8) (2000), 1075-1081.
50. R.G. Will, M. Zeidler, G.E. Stewart and M.A. Macleod et al., Diagnosis of new variant Creutzfeldt-Jakob disease, Ann Neurol 47(5) (2000), 575-582.
51. L. Monari, S.G. Chen, P. Brown and P. Parchi et al., Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism, Proc Natl Acad Sci USA 91(7) (1994), 2839-2842.
52. P. Parchi, A. Giese, S. Capellari and P. Brown et al., The molecular and clinico-pathologic spectrum of phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD), Neurology 50(Suppl. 4) (1998), A336.
53. P. Parchi, A. Giese, S. Capellari and P. Brown et al., Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects, Ann Neurol 46(2) (1999), 224-233.
54. W.J. Schulz-Schaeffer, A. Giese, O. Windl and H.A. Kretzschmar, Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease, Clin Neuropathol 15(6) (1996), 353-357.
55. I. Zerr, W.J. Schulz-Schaeffer, A. Giese and M. Bodemer et al., Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants, Ann Neurol 48(3) (2000), 323-329.
56. J. Collinge, K.C. Sidle, J. Meads, J. Ironside and A.F. Hill, Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD, Nature 383(6602) (1996), 685-690.
57. A. Aguzzi, Neuro-immune connection in spread of prions in the body? Lancet 349(9054) (1997), 742-743.
58. M.E. Bruce, K.L. Brown, N.A. Mabbott, C.F. Farquhar and M. Jeffrey, Follicular dendritic cells in TSE pathogenesis, Immunol Today 21(9) (2000), 442-446.
59. M.A. Klein, R. Frigg, E. Flechsig and A.J. Raeber et al., A crucial role for B cells in neuroinvasive scrapie, Nature 390(6661) (1997), 687-690.
60. M.A. Klein, R. Frigg, A.J. Raeber and E. Flechsig et al., PrP expression in B lymphocytes is not required for prion neuroinvasion [see comments], Nat Med 4(12) (1998), 1429-1433.
61. M. Beekes and P.A. McBride, Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie, Neurosci Lett 278(3) (2000), 181-184.
62. F.L. Heppner, A.D. Christ, M.A. Klein and M. Prinz et al., Transepithelial prion transport by M cells, Nat Med 7(9) (2001), 976-977.
63. P.A. McBride and M. Beekes, Pathological PrP is abundant in sympathetic and sensory ganglia of hamsters fed with scrapie, Neurosci Lett 265(2) (1999), 135-138.
64. M. Beekes, P.A. McBride and E. Baldauf, Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie, J Gen Virol 79(Pt 3) (1998), 601-607.
65. P.A. McBride, W.J. Schulz-Schaeffer, M. Donaldson and M. Bruce et al., Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves, J Virol 75(19) (2001), 9320-9327.
66. R.G. Will, A. Alperovitch, S. Poser and M. Pocchiari et al., Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD, Ann Neurol 43(6) (1998), 763-767.
67. T. Billette de Villemeur, J.P. Deslys, A. Pradel and C. Soubrie et al., Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France, Neurology 47(3) (1996), 690-695.
68. P. Brown, M.A. Preece and R.G. Will, "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease, Lancet 340(8810) (1992), 24-27.
69. C.L. Masters, J.O. Harris, D.C. Gajdusek and C.J.J. Gibbs et al., Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering, Ann Neurol 5(2) (1979), 177-188.
70. WHO, Consensus on criteria for sporadic CJD, Geneve, 1998.
71. B.J. Steinhoff, S. Racker, G. Herrendorf and S. Poser et al., Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease, Arch Neurol 53(2) (1996), 162-166.
72. I. Zerr, M. Bodemer, O. Gefeller and M. Otto et al., Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease, Ann Neurol 43(1) (1998), 32-40.
73. M. Finkenstaedt, A. Szudra, I. Zerr and S. Poser et al., MR imaging of Creutzfeldt-Jakob disease, Radiology 199(3) (1996), 793-798.
74. A. Schroter, I. Zerr, K. Henkel and H.J. Tschampa et al., Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease, Arch Neurol 57(12) (2000), 1751-1757.
75. M. Zeidler, E.C. Johnstone, R.W. Bamber and C.M. Dickens et al., New variant Creutzfeldt-Jakob disease: psychiatric features, Lancet 350(9082) (1997), 908-910.
76. M. Zeidler, G.E. Stewart, C.R. Barraclough and D.E. Bateman et al., New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests, Lancet 350(9082) (1997), 903-907.
77. M. Zeidler, R.G. Will, J.W. Ironside, R. Sellar and J. Wardlaw, Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Magnetic resonance imaging is not a sensitive test for Creutzfeldt-Jakob disease [letter], Bmj 312(7034) (1996), 844.
78. M. Zeidler, R.J. Sellar, D.A. Collie and R. Knight et al., The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease, Lancet 355(9213) (2000), 1412-1418.
79. A. Coulthard, K. Hall, P.T. English and P.G. Ince et al., Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease, Br J Radiol 72(860) (1999), 742-748.
80. S. Poser, B. Mollenhauer, A. Kraubeta and I. Zerr et al., How to improve the clinical diagnosis of Creutzfeldt-Jakob disease, Brain 122(Pt 12) (1999), 2345-2351.
81. S. Poser, I. Zerr, A. Schroeter and M. Otto et al., Clinical and differential diagnosis of Creutzfeldt-Jakob disease, Arch Virol Suppl 16 (2000), 153-159.
82. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti and J.L. Cummings et al., Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology 43(2) (1993), 250-260.
83. C. Holmes, N. Cairns, P. Lantos and A. Mann, Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies, Br J Psychiatry 174 (1999), 45-50.
84. P.J. Shaw, T.J. Walls, P.K. Newman, P.G. Cleland and N.E. Cartlidge, Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers - report of 5 cases, Neurology 41(2 (Pt 1)) (1991), 228-233.
85. M. Seipelt, I. Zerr, R. Nau and B. Mollenhauer et al., Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry 66(2) (1999), 172-176.
86. M. Hartmann, B. Schaner, K. Scheglmann, A. Bucking and R. Pfister, [Hashimoto encephalopathy: steroid-sensitive encephalopathy in Hashimoto thyroiditis], Nervenarzt 71(6) (2000), 489-494.
87. L.E. Hernandez Echebarria, A. Saiz, F. Graus and J. Tejada et al., Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy, Neurology 54(7) (2000), 1539-1540.
88. H.A. Kretzschmar and M. Neumann, [Neuropathological diagnosis of neurodegenerative and dementia diseases], Pathologe 21(5) (2000), 364-374.
89. V.M. Lee, M. Goedert and J.Q. Trojanowski, Neurodegenerative tauopathies, Annu Rev Neurosci 24 (2001), 1121-1159.
90. S. Gilman, P.A. Low, N. Quinn and A. Albanese et al., Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci 163(1) (1999), 94-98.
91. J.B. Schulz, T. Klockgether, D. Petersen and M. Jauch et al., Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT, J Neurol Neurosurg Psychiatry 57(9) (1994), 1047-1056.
92. A. Schrag, D. Kingsley, C. Phatouros and C.J. Mathias et al., Clinical usefulness of magnetic resonance imaging in multiple system atrophy, J Neurol Neurosurg Psychiatry 65(1) (1998), 65-71.
93. I.G. McKeith, D. Galasko, K. Kosaka and E.K. Perry et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology 47(5) (1996), 1113-1124.
94. G. Ransmayr, G.K. Wenning, K. Seppi, K. Jellinger and W. Poewe, [Dementia with Lewy bodies], Nervenarzt 71(12) (2000), 929-935.
95. I.G. McKeith, C.G. Ballard, R.H. Perry and P.G. Ince et al., Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies, Neurology 54(5) (2000), 1050-1058.
96. L.A. Klatka, E.D. Louis and R.B. Schiffer, Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups, Neurology 47(5) (1996), 1148-1152.
97. H.J. Tschampa, M. Neumann, I. Zerr and K. Henkel et al., Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry 71(1) (2001), 33-39.
98. M.G. Spillantini, M.L. Schmidt, V.M. Lee and J.Q. Trojanowski et al., Alpha-synuclein in Lewy bodies, Nature 388(6645) (1997), 839-840.
99. H.J. Tschampa, W. Schulz-Schaeffer, J. Wiltfang and S. Poser et al., Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies, Neurology 56(4) (2001), 576.
100. M. Cruts, C.M. van Duijn, H. Backhovens and M. Van den Broeck et al., Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease, Hum Mol Genet 7(1) (1998), 43-51.
101. C. Czech, V. Monning, P.J. Tienari and T. Hartmann et al., Apolipoprotein E-epsilon 4 allele and Alzheimer's disease, Lancet 342(8882) (1993), 1309.
102. C.M. van Duijn, P. de Knijff, M. Cruts and A. Wehnert et al., Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease, Nat Genet 7(1) (1994), 74-78.
103. N.J. Cairns, P.F. Atkinson, T. Kovacs and A.J. Lees et al., Apolipoprotein E e4 allele frequency in patients with multiple system atrophy, Neurosci Lett 221(2-3) (1997), 161-164.
104. J. Chapman, L. Cervenakova, R.B. Petersen and H.S. Lee et al., APOE in non-Alzheimer amyloidoses: transmissible spongiform encephalopathies, Neurology 51(2) (1998), 548-553.
105. I. Zerr, M. Helmhold, S. Poser, V.W. Armstrong and T. Weber, Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease, Arch Neurol 53(12) (1996), 1233-1238.
106. APA, Diagnostic and Statistical Manual of Mental Disorders, (Fourth Edition ed.), Washington, DC: American Psychiatric Association, 1994, pp. 142-143.
107. WHO, ICD-10 Internationale Klassifikation psychischer Störungen, ed. Weltgesundheitsorganisation, Verlag Hans Huber, 1993.
108. G. McKhann, D. Drachman, M. Folstein and R. Katzman et al., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34(7) (1984), 939-944.
109. P. Scheltens and E.S. Korf, Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias, Curr Opin Neurol 13(4) (2000), 391-396.
110. C.L. Masters, G. Simms, N.A. Weinman and G. Multhaup et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci USA 82(12) (1985), 4245-4249.
111. H. Akiyama, S. Barger, S. Barnum and B. Bradt et al., Inflammation and Alzheimer's disease, Neurobiol Aging 21(3) (2000), 383-421.
112. V.M. Lee, B.J. Balin, L. Otvos, Jr. and J.Q. Trojanowski, A68: a major subunit of paired helical filaments and derivatized forms of normal Tau, Science 251(4994) (1991), 675-678.
113. S.S. Mirra, A. Heyman, D. McKeel and S.M. Sumi et al., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology 41(4) (1991), 479-486.
114. H. Braak and E. Braak, Diagnostic criteria for neuropathologic assessment of Alzheimer's disease, Neurobiol Aging 18(4 Suppl) (1997), S85-88.
115. B.T. Hyman and J.Q. Trojanowski, Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimers Disease, J. Neuropath. and Exper. Neurol. 56(10) (1997), 1095-1097.
116. M. Miyazono, T. Kitamoto, T. Iwaki and J. Tateishi, Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome, Acta Neuropathol (Berl) 83(4) (1992), 333-339.
117. H.A. Kretzschmar, J.W. Ironside, S.J. DeArmond and J. Tateishi, Diagnostic criteria for sporadic Creutzfeldt-Jakob disease, Arch Neurol 53(9) (1996), 913-920.
118. B. Chesebro, R. Race, K. Wehrly and J. Nishio et al., Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain, Nature 315(6017) (1985), 331-333.
119. R. Kordek, P.P. Liberski, R. Yanagihara, S. Isaacson and D.C. Gajdusek, Molecular analysis of prion protein (PrP) and glial fibrillary acidic protein (GFAP) transcripts in experimental Creutzfeldt-Jakob disease in mice, Acta Neurobiol Exp 57(2) (1997), 85-90.
120. F. Lazarini, J.P. Deslys and D. Dormont, Variations in prion protein and glial fibrillary acidic protein mRNAs in the brain of scrapie-infected newborn mouse, J Gen Virol (1992).
121. L. Manuelidis, W. Fritch and Y.G. Xi, Evolution of a strain of CJD that induces BSE-like plaques, Science 277(5322) (1997), 94-98.
122. P Brown, R.G. Rohwer, B.C. Dunstan and C. MacAuley et al., The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy, Transfusion 38(9) (1998), 810-816.
123. P. Brown, L. Cervenakova, L.M. McShane and P. Barber et al., Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans [see comments], Transfusion 39(11-12) (1999), 1169-1178.
124. C. Riemer, I. Queck, D. Simon, R. Kurth and M. Baier, Identification of upregulated genes in scrapie-infected brain tissue [In Process Citation], J Virol 74(21) (2000), 10245-10248.
125. P. Parchi, S. Capellari, S.G. Chen and R.B. Petersen et al., Typing prion isoforms, Nature 386(6622) (1997), 232-234.
126. MacKenzie, Testing for BSE, New Scientist 13 (June 1998), 4.
127. M. Moser and B. Oesch, Testing for BSE, New Scientist 4 (July 1998), 52.
128. Bundesamt für Veterinärwesen, B.f.G., Bundesamt für Landwirtschaft (Schweiz), BSE-Überwachung wird verstärkt, Pressemitteilung 25 (February 1999).
129. Prionics, webpage - www.prionics.com, 1999.
130. A.F. Hill, R.J. Butterworth, S. Joiner and G. Jackson et al., Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples, Lancet 353(9148) (1999), 183-189.
131. M. Zeidler, R. Knight, G. Stewart and J.W. Ironside et al., Diagnosis of Creutzfeldt-Jakob disease. Routine tonsil biopsy for diagnosis of new variant Creutzfeldt-Jakob disease is not justified, Bmj 318(7182) (1999), 538A.
132. F. Tagliavini, F. Prelli, M. Porro and M. Salmona et al., A soluble form of prion protein in human cerebrospinal fluid: implications for prion-related encephalopathies, Biochem Biophys Res Commun 184(3) (1992), 1398-1404.
133. B.S. Wong, A.J. Green, R. Li and Z. Xie et al., Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease, J Pathol 194(1) (2001), 9-14.
134. J. Bieschke, A. Giese, W. Schulz-Schaeffer and I. Zerr et al., Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets, Proc Natl Acad Sci USA 97(10) (2000), 5468-5473.
135. C. Korth, B. Stierli, P. Streit and M. Moser et al., Prion (PrPSc)-specific epitope defined by a monoclonal antibody, Nature 390(6655) (1997), 74-77.
136. G.P. Saborio, B. Permanne and C. Soto, Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding, Nature 411(6839) (2001), 810-813.
137. G.P. Saborio, C. Soto, R.J. Kascsak and E. Levy et al., Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone, Biochem Biophys Res Commun 258(2) (1999), 470-475.
138. H.B. Urnovitz, J.J. Tuite, J.M. Higashida and W.H. Murphy, RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11.2, Clin Diagn Lab Immunol 6(3) (1999), 330-335.
139. J. Kneipp, P. Lasch, E. Baldauf, M. Beekes and D. Naumann, Detection of pathological molecular alterations in scrapie-infected hamster brain by Fourier transform infrared (FTIR) spectroscopy, Biochim Biophys Acta 1501(2-3) (2000), 189-199.
140. J. Kneipp, M. Beekes, P. Lasch and D. Naumann, Molecular changes of preclinical scrapie can be detected by infrared spectroscopy, J Neurosci 22(8) (2002), 2989-2997.
141. T. Jimi, Y. Wakayama, S. Shibuya and H. Nakata et al., High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease, Clin Chim Acta 211(1-2) (1992), 37-46.
142. M.G. Harrington, C.R. Merril, D.M. Asher and D.C. Gajdusek, Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, N Engl J Med 315(5) (1986), 279-283.
143. I. Zerr, M. Bodemer, M. Otto and S. Poser et al., Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid, Lancet 348(9031) (1996), 846-849.
144. G. Hsich, K. Kenney, C.J. Gibbs, K.H. Lee and M.G. Harrington, The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies, N Engl J Med 335(13) (1996), 924-930.
145. A. Aitken, 14-3-3 proteins on the MAP, Trends Biochem Sci 20(3) (1995), 95-97.
146. J. Wiltfang, M. Otto, H.C. Baxter and M. Bodemer et al., Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurochem 73(6) (1999), 2485-2490.
147. R.G. Will, M. Zeidler, P. Brown and M. Harrington et al., Cerebrospinal-fluid test for new variant Creutzfeldt-Jakob disease, Lancet 348 (1996), 955.
148. A.J. Green, E.J. Thompson, G.E. Stewart and M. Zeidler et al., Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry 70(6) (2001), 744-748.
149. K. Kenney, C. Brechtel, H. Takahashi and K. Kurohara et al., An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients, Ann Neurol 48(3) (2000), 395-398.
150. J. Leuck, K. Peoch, J.L. Laplanche and E. Grabar et al., A novel binding assay for detection of 14-3-3 protein in cerebrospinal fluid from Creutzfeldt-Jakob patients, Cell Mol Biol (Noisy-Le-Grand) 46(7) (2000), 1291-1296.
151. C. Jacobi and H. Reiber, Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid, Clin Chim Acta 177 (1986), 49-54.
152. I. Zerr, M. Bodemer, S. Räcker and S. Grosche et al., Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease, Lancet 345 (1995), 1609-1610.
153. H. Braak, E. Braak, J. Bohl and H. Bratzke, Evolution of Alzheimer's disease related cortical lesions, J Neural Transm 54 (1998), 97-106.
154. I. Grundke-Iqbal, K. Iqbal, Y.C. Tung and M. Quinlan et al., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA 83(13) (1986), 4913-4917.
155. D.W. Cleveland, S.Y. Hwo and M.W. Kirschner, Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin, J Mol Biol 116(2) (1977), 207-225.
156. P. LoPresti, S. Szuchet, S.C. Papasozomenos, R.P. Zinkowski and L.I. Binder, Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes, Proc Natl Acad Sci USA 92(22) (1995), 10369-10373.
157. R.L. Neve, P. Harris, K.S. Kosik, D.M. Kurnit and T.A. Donlon, Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2, Brain Res 387(3) (1986), 271-280.
158. A. Andreadis, W.M. Brown and K.S. Kosik, Structure and novel exons of the human tau gene, Biochemistry 31(43) (1992), 10626-10633.
159. M. Goedert and R. Jakes, Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization, Embo J 9(13) (1990), 4225-4230.
160. B.L. Goode, P.E. Denis, D. Panda and M.J. Radeke et al., Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly, Mol Biol Cell 8(2) (1997), 353-365.
161. L. Buee, T. Bussiere, V. Buee-Scherrer, A. Delacourte and P.R. Hof, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Brain Res Rev 33(1) (2000), 95-130.
162. M.L. Billingsley and R.L. Kincaid, Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem J 323(Pt 3) (1997), 577-591.
163. J.P. Brion, A.M. Couck, E. Passareiro and J. Flament-Durand, Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study, J Submicrosc Cytol 17(1) (1985), 89-96.
164. P. Seubert, M. Mawal-Dewan, R. Harbour and R. Jakes et al., Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau, J Biol Chem 270(32) (1995), 18917-18922.
165. N. Andreasen, E. Vanmechelen, A. Van de Voorde and P. Davidsson et al., Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study, J Neurol Neurosurg Psychiatry 64(3) (1998), 298-305.
166. F. Hulstaert, K. Blennow, A. Ivanoiu and H.C. Schoonderwaldt et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology 52(8) (1999), 1555-1562.
167. M. Otto, J. Wiltfang, H. Tumani and I. Zerr et al., Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurosci Lett 225(3) (1997), 210-212.
168. M. Otto, J. Wiltfang, L. Cepek and M. Neumann et al., Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease, Neurology 58(2) (2002), 192-197.
169. K. Buch, M. Riemenschneider, P. Bartenstein and F. Willoch et al., Tau-Protein: Ein potentieller biologischer Indikator zur Früherkennung der Alzheimer-Krankheit, Nervenarzt 69(5) (1998), 379-385.
170. E. Vanmechelen, H. Vanderstichele, F. Hulstaert and N. Andreasen et al., Cerebrospinal fluid tau and beta-amyloid((1-42)) in dementia disorders, Mech Ageing Dev 122(16) (2001), 2005-2011.
171. E. Kapaki, K. Kilidireas, G.P. Paraskevas, M. Michalopoulou and E. Patsouris, Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 71(3) (2001), 401-403.
172. N. Itoh, H. Arai, K. Urakami and K. Ishiguro et al., Largescale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease, Ann Neurol 50(2) (2001), 150-156.
173. B. Van Everbroeck, A. Green, E. Vanmechelen and H. Vanderstichele et al., Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry 73 (2002), 79-81.
174. R.E. Mrak, J.G. Sheng and W.S. Griffin, Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease, J Neuropathol Exp Neurol 55(3) (1996), 273-279.
175. C.L. Masters, R.G. Rohwer, M.C. Franko, P. Brown and D.C. Gajdusek, The sequential development of spongiform change and gliosis of scrapie in the golden Syrian hamster, J Neuropathol Exp Neurol 43(3) (1984), 242-252.
176. B.W. Schäfer and C.W. Heizmann, The S100 family of EF-hand calcium-binding proteins: functions and pathology, Trends Biochem Sci 21(4) (1996), 134-140.
177. B.W. Schäfer, R. Wicki, D. Engelkamp, M.G. Mattei and C.W. Heizmann, Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family, Genomics 25(3) (1995), 638-643.
178. Y. Iwasaki, T. Shiojima and M. Kinoshita, S100 beta prevents the death of motor neurons in newborn rats after sciatic nerve section [In Process Citation], J Neurol Sci 151(1) (1997), 7-12.
179. H.D. Abraha, L.C. Fuller, A.W. Du Vivier, E.M. Higgins and R.A. Sherwood, Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma, Br J Dermatol 137(3) (1997), 381-385.
180. U. Missler, M. Wiesmann, C. Friedrich and M. Kaps, S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke, Stroke 28(10) (1997), 1956-1960.
181. M. Herrmann, P. Vos, M.T. Wunderlich, C.H. de Bruijn and K.J. Lamers, Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein, Stroke 31(11) (2000), 2670-2677.
182. H. Ehrenreich, M. Hasselblatt, C. Dembowski and L. Cepek et al., Erythropoietin therapy for acute stroke is both safe and beneficial, Mol Med 8(8) (2002), 495-505.
183. K. Waterloo, I. Ingebrigtsen and B. Romner, Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury, Acta Neurochir. (Wien) 139 (1997), 26-32.
184. M. Otto, S. Holthusen, E. Bahn and N. Söhnchen et al., Boxing and running lead to a rise in serum levels of S-100B protein, Int J Sports Med 21(8) (2000), 551-555.
185. M. Otto, H. Stein, A. Szudra and I. Zerr et al., S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurol 244(9) (1997), 566-570.
186. A. Green, R. Knight, G. Stewart and M. Rossor et al. Biochemical markers of brain damage in the diagnosis of Creutzfeldt-Jakob disease, in Biochemical Marker for Brain Damage, Lund, 1998.
187. P Beaudry, P. Cohen, J.P. Brandel and N. Delasnerie-Laupretre et al., 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Dement Geriatr Cogn Disord 10(1) (1999), 40-46.
188. M. Otto, J. Wiltfang, E. Schütz and I. Zerr et al., Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study, BMJ 316(7131) (1998), 577-582.
189. L. Maeck, J. Meller, M. Otto and G. Stiens et al., Abeta peptide(1-42), Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia, Neurosci Lett 333(1) (2002), 33-36.
190. H. Reiber, Dynamics of brain-derived proteins in cerebrospinal fluid, Clin Chim Acta 310(2) (2001), 173-186.
191. N.N. Poleshchuk, V.I. Votyakov, Y. Ilkevich and G.P. Duboiskaya et al., Structural and functional changes of blood-brain barrier and indication of prion amyloid filaments in experimental amyotrophic leucospongiosis, Acta Virol Praha 36(3) (1992), 293-303.
192. A.W. Vorbrodt, A.S. Lossinsky, H.M. Wisniewski, R.C. Moretz and L. Iwanowski, Ultrastructural cytochemical studies of cerebral microvasculature in scrapie infected mice, Acta Neuropathol Berl 53(3) (1981), 203-211.
193. A.W. Vorbrodt, D.H. Dobrogowska, M. Tarnawski, H.C. Meeker and R.I. Carp, Immunocytochemical evaluation of blood-brain barrier to endogenous albumin in scrapie-infected mice, Acta Neuropathol (Berl) 93(4) (1997), 341-348.
194. H.M. Wisniewski, A.S. Lossinsky, R.C. Moretz and A.W. Vorbrodt et al., Increased blood-brain barrier permeability in scrapie-infected mice, J Neuropathol Exp Neurol 42(6) (1983), 615-626.
195. M. Otto, M. Beekes, J. Witfang and E. Bahn et al., Elevated levels of serum S100 beta protein in scrapie hamsters, J. Neurovirol. 4 (1998), 572-573.
196. M. Beekes, M. Otto, J. Wiltfang and E. Bahn et al., Late increase of serum S100 beta protein levels in hamsters after oral or intraperitoneal infection with scrapie agent, J Infect Dis 180(2) (1999), 518-520.
197. A.J. Green, R. Jackman, T.A. Marshall and E.J. Thompson, Increased S-100b in the cerebrospinal fluid of some cattle with bovine spongiform encephalopathy, Vet Rec 145(4) (1999), 107-109.
198. J.L. Riond, P. Hartmann, H.I. Joller-Jemelka and U. Braun, S-100 and bovine spongiform encephalopathy, Vet Rec 145(4) (1999), 114-115.
199. F. Lazarini, P. Castelnau, J.F. Chermann, J.P. Deslys and D. Dormont, Modulation of prion protein gene expression by growth factors in cultured mouse astrocytes and PC-12 cells, Brain Res Mol Brain Res 22(1-4) (1994), 268-274.
200. U. Missler, M. Wiesmann, G. Wittmann, O. Magerkurth and H. Hagenstrom, Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results, Clin Chem 45(1) (1999), 138-141.
201. G.G. Glenner and C.W. Wong, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun 120(3) (1984), 885-890.
202. M. Shoji, T.E. Golde, J. Ghiso and T.T. Cheung et al., Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258(5079) (1992), 126-129.
203. S.A. Gravina, L. Ho, C.B. Eckman and K.E. Long et al., Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43), J Biol Chem 270(13) (1995), 7013-7016.
204. J. Wiltfang, H. Esselmann, P. Cupers and M. Neumann et al., Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells, J Biol Chem 276(46) (2001), 42645-42657.
205. J. Wiltfang, H. Esselmann, M. Bibl and A. Smirnov et al., Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation, J Neurochem 81(3) (2002), 481-496.
206. R. Motter, C. Vigo-Pelfrey, D. Kholodenko and R. Barbour et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann Neurol 38(4) (1995), 643-648.
207. N. Andreasen, C. Hesse, P. Davidsson and L. Minthon et al., Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease, Arch Neurol 56(6) (1999), 673-680.
208. D. Galasko, L. Chang, R. Motter and C.M. Clark et al., High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype, Arch Neurol 55(7) (1998), 937-945.
209. D. Galasko, Clinical utility of cerebrospinal fluid tau and Ab42 in Alzheimer's diseases, in International Symposium oN Ageing and Dementia, Universität Graz, 1997.
210. C. Hesse, L. Minthon and A. Wallin et al., Tau protein and β-amyloid(1-42) in cerebrospinal fluid from Alzheimer's disease patients and controls, Neurobiol. Aging 19 (1998), S163.
211. M. Kanai, E. Matsubara, K. Isoe and K. Urakami et al., Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan, Ann Neurol 44(1) (1998), 17-26.
212. M. Otto, H. Esselmann, W. Schulz-Schaeffer and M. Neumann et al., Decreased levels of Abeta 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseae, Neurology 54 (2000), 1099-1102.
213. M. Pitschke, R. Prior, M. Haupt and D. Riesner, Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy, Nat Med 4(7) (1998), 832-834.
214. J. Wiltfang, N. Arold and V. Neuhoff, A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity, Elektrophoresis 12 (1991), 352-366.
215. K. Peoc'h, H.C. Schroder, J. Laplanche, S. Ramljak and W.E. Muller, Determination of 14-3-3 protein levels in cerebrospinal fluid from Creutzfeldt-Jakob patients by a highly sensitive capture assay, Neurosci Lett 301(3) (2001), 167-170. 209